

Lauren Fishbein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6296221/publications.pdf>

Version: 2024-02-01

35
papers

2,180
citations

471509

17
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

3397
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
2	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3059-3068.	7.0	366
3	Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing. <i>Annals of Surgical Oncology</i> , 2013, 20, 1444-1450.	1.5	182
4	Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. <i>Cancer Genetics</i> , 2012, 205, 1-11.	0.4	177
5	Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. <i>Nature Communications</i> , 2015, 6, 6140.	12.8	143
6	Pheochromocytoma and Paraganglioma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 135-150.	2.2	127
7	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	1.1	88
8	Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma. <i>Journal of Clinical Hypertension</i> , 2013, 15, 428-434.	2.0	62
9	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. <i>Pancreas</i> , 2021, 50, 469-493.	1.1	55
10	Development of new preclinical models to advance adrenocortical carcinoma research. <i>Endocrine-Related Cancer</i> , 2018, 25, 437-451.	3.1	45
11	Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4661-e4670.	3.6	40
12	In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells. <i>Molecular Carcinogenesis</i> , 2007, 46, 512-523.	2.7	39
13	Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. <i>JCI Insight</i> , 2016, 1, e88207.	5.0	38
14	Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2019, 11, 1121.	3.7	36
15	Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. <i>Cancer Genetics and Cytogenetics</i> , 2005, 157, 181-186.	1.0	26
16	Genetics of pheochromocytoma and paraganglioma. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 283-290.	2.3	22
17	Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma/pheochromocytoma syndrome. <i>Genetics in Medicine</i> , 2020, 22, 2101-2107.	2.4	20
18	The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2020, 129, 1135-1143.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. <i>Endocrinology</i> , 2018, 159, 2532-2544.	2.8	19
20	Chromaffin cell biology: inferences from The Cancer Genome Atlas. <i>Cell and Tissue Research</i> , 2018, 372, 339-346.	2.9	17
21	Head and Neck Paragangliomas: An Update on the Molecular Classification, State-of-the-Art Imaging, and Management Recommendations. <i>Radiology Imaging Cancer</i> , 2022, 4, e210088.	1.6	17
22	Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?. <i>Current Cardiology Reports</i> , 2019, 21, 104.	2.9	16
23	SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas. <i>Cell Reports</i> , 2022, 38, 110453.	6.4	16
24	Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4028-e4038.	3.6	13
25	Targeted genomic analysis of 364 adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2021, 28, 671-681.	3.1	13
26	Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression. <i>Molecular Cancer Research</i> , 2021, 19, 1476-1485.	3.4	11
27	The Jewel in the Crown: Specific Aims Section of Investigator-Initiated Grant Proposals. <i>Journal of the Endocrine Society</i> , 2017, 1, 1194-1202.	0.2	8
28	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e350-e364.	3.6	8
29	Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1159-1169.	3.6	7
30	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. <i>Oncotarget</i> , 2016, 7, 48577-48585.	1.8	6
31	Pheochromocytoma and Paraganglioma Susceptibility Genes. <i>JAMA Oncology</i> , 2017, 3, 1212.	7.1	4
32	Discovery of new susceptibility genes: proceed cautiously. <i>Genetics in Medicine</i> , 2018, 20, 1512-1514.	2.4	3
33	Case report of a paraganglioma arising from a mature cystic teratoma of the ovary. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100537.	0.6	3
34	Case of Metastatic Pheochromocytoma and Meningiomas in a Patient With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2022, 6, e2100251.	3.0	1
35	Impact of COVID-19 on individuals with paraganglioma/pheochromocytoma history and/or hereditary risk.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10613-10613.	1.6	0